Soligenix, Inc.

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Biotechnology
MRNAModerna, Inc. -4.64%68.670.0%$2262.75m
NVAXNovavax, Inc. -14.42%152.77251.8%$1145.00m
SRNESorrento Therapeutics, Inc. -11.29%16.701.5%$798.24m
GILDGilead Sciences, Inc. -0.10%68.441.0%$563.72m
AMGNAmgen, Inc. -0.69%236.521.3%$473.78m
REGNRegeneron Pharmaceuticals, Inc. -1.79%597.352.7%$396.09m
BNTXBioNTech SE -8.49%67.670.0%$363.90m
VRTXVertex Pharmaceuticals, Inc. -1.79%263.931.9%$362.86m
BIIBBiogen, Inc. -0.25%299.511.6%$362.76m
ILMNIllumina, Inc. -1.72%347.273.5%$336.26m
VXRTVaxart, Inc. -3.25%9.090.0%$286.55m
ATNMActinium Pharmaceuticals, Inc. 1000.00%9.420.6%$240.99m
EBSEmergent BioSolutions, Inc. -2.54%126.886.4%$183.59m
ALXNAlexion Pharmaceuticals, Inc. -0.51%101.362.0%$165.68m
SGENSeattle Genetics, Inc. -1.57%155.226.2%$158.16m

Company Profile

Soligenix, Inc. is a late-stage biopharmaceutical company, which engages in the development and commercialization of products to treat rare disease. It operates through Specialized BioTherapeutics and Public Health Solutions segments. The Specialized BioTherapeutics segment focuses in the development of a novel photodynamic therapy (SGX301) utilizing topical synthetic hypericin activated with safe visible fluorescent light for the treatment of cutaneous T-cell lymphoma. The Public Health Solutions solutions comprises active development programs for RiVax, ricin toxin vaccine candidate and SGX943, a therapeutic candidate for antibiotic resistant and emerging infectious disease. The company was founded in 1987 and is headquartered Princeton, NJ.